Skip to main content

Advertisement

Figure 1 | Clinical Proteomics

Figure 1

From: A novel multiplexed immunoassay identifies CEA, IL-8 and prolactin as prospective markers for Dukes’ stages A-D colorectal cancers

Figure 1

Panels (P) (A, B, C, D & E) representing protein abundance data for CEA (A), IL-8 (B) prolactin (C), amphiregulin (D) and PDGF-BB (E) in individual Dukes’ stage A, B, C & D with E controls; pooled group (defined control, non-malignant, malignant groups). Values were determined by Proseek PEA using CRC patient EDTA plasmas and was based on z-scores (log2 scale).

Back to article page